U.S. national surveillance data show clinical cases of Candida auris climbed from 2,882 in 2022 to 6,197 in 2024—more than doubling in two years—according to a CDC Morbidity and Mortality Weekly Report summary cited in the report. Provisional figures suggest the rise continued in 2026 with dozens of states reporting increasing case counts. The report highlights why containment remains challenging: C. auris can persist on hospital surfaces for weeks and is often spread by colonized patients without symptoms, complicating outbreak control in healthcare and long-term care settings. It also notes that nearly 88% of clinical cases occurred in people aged 45 or older and that C. auris has been detected on healthcare workers’ gloves and gowns after a significant fraction of care interactions in a multicenter colonization study. For biotech and diagnostics, the surge reinforces demand for improved screening, faster detection, and antifungal development as the CDC treats C. auris as an urgent antimicrobial-resistance threat.